1
|
Kim HJ, Oh GS, Shen A, Lee SB, Choe SK, Kwon KB, Lee S, Seo KS, Kwak TH, Park R, So HS. Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment. Cell Death Dis 2014; 5:e1292. [PMID: 24922076 PMCID: PMC4611728 DOI: 10.1038/cddis.2014.255] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Revised: 04/18/2014] [Accepted: 05/09/2014] [Indexed: 12/20/2022]
Abstract
Cisplatin (cis-diaminedichloroplatinum-II) is an extensively used chemotherapeutic agent, and one of its most adverse effects is ototoxicity. A number of studies have demonstrated that these effects are related to oxidative stress and DNA damage. However, the precise mechanism underlying cisplatin-associated ototoxicity is still unclear. The cofactor nicotinamide adenine dinucleotide (NAD(+)) has emerged as a key regulator of cellular energy metabolism and homeostasis. Here, we demonstrate for the first time that, in cisplatin-mediated ototoxicity, the levels and activities of SIRT1 are suppressed by the reduction of intracellular NAD(+) levels. We provide evidence that the decrease in SIRT1 activity and expression facilitated by increasing poly(ADP-ribose) transferase (PARP)-1 activation and microRNA-34a through p53 activation aggravates cisplatin-mediated ototoxicity. Moreover, we show that the induction of cellular NAD(+) levels using β-lapachone (β-Lap), whose intracellular target is NQO1, prevents the toxic effects of cisplatin through the regulation of PARP-1 and SIRT1 activity. These results suggest that direct modulation of cellular NAD(+) levels by pharmacological agents could be a promising therapeutic approach for protection from cisplatin-induced ototoxicity.
Collapse
Affiliation(s)
- H-J Kim
- Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea
| | - G-S Oh
- Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea
| | - A Shen
- 1] Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea [2] BK21plus Program and Department of Smart Life-Care Convergence, Wonkwang University Graduate School, Jeonbuk, Republic of Korea
| | - S-B Lee
- 1] Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea [2] BK21plus Program and Department of Smart Life-Care Convergence, Wonkwang University Graduate School, Jeonbuk, Republic of Korea
| | - S-K Choe
- Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea
| | - K-B Kwon
- 1] Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea [2] BK21plus Program and Department of Smart Life-Care Convergence, Wonkwang University Graduate School, Jeonbuk, Republic of Korea [3] Department of Oriental Medical Physiology, College of Korean Medicine, Wonkwang University, Jeonbuk, Republic of Korea
| | - S Lee
- Life Science Research Center, KT&G Life Sciences, Suwon, Republic of Korea
| | - K-S Seo
- Life Science Research Center, KT&G Life Sciences, Suwon, Republic of Korea
| | - T H Kwak
- Life Science Research Center, KT&G Life Sciences, Suwon, Republic of Korea
| | - R Park
- 1] Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea [2] BK21plus Program and Department of Smart Life-Care Convergence, Wonkwang University Graduate School, Jeonbuk, Republic of Korea
| | - H-S So
- 1] Center for Metabolic Function Regulation, Department of Microbiology, Wonkwang University School of Medicine, Jeonbuk, Republic of Korea [2] BK21plus Program and Department of Smart Life-Care Convergence, Wonkwang University Graduate School, Jeonbuk, Republic of Korea
| |
Collapse
|
2
|
Abstract
Many Hox proteins are thought to require Pbx and Meis co-factors to specify cell identity during embryogenesis. Here we demonstrate that Meis3 synergizes with Pbx4 and Hoxb1b in promoting hindbrain fates in the zebrafish. We find that Hoxb1b and Pbx4 act together to induce ectopic hoxb1a expression in rhombomere 2 of the hindbrain. In contrast, Hoxb1b and Pbx4 acting together with Meis3 induce hoxb1a, hoxb2, krox20 and valentino expression rostrally and cause extensive transformation of forebrain and midbrain fates to hindbrain fates, including differentiation of excess rhombomere 4-specific Mauthner neurons. This synergistic effect requires that Hoxb1b and Meis3 have intact Pbx-interaction domains, suggesting that their in vivo activity is dependent on binding to Pbx4. In the case of Meis3, binding to Pbx4 is also required for nuclear access. Our results are consistent with Hoxb1b and Meis3 interacting with Pbx4 to form complexes that regulate hindbrain development during zebrafish embryogenesis.
Collapse
Affiliation(s)
- N Vlachakis
- Department of Biochemistry and Molecular Pharmacology, and Program in Neuroscience, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | | | | |
Collapse
|